Sandra Leung - Bristol-Myers Squibb General Counsel, Corporate Secretary
Executive
Ms. Sandra Leung serves as Executive Vice President, General Counsel of the Company. From 2007 to 2014 General Counsel and Corporationrationrate Secretary, 2014 to 2015 Executive Vice President, General Counsel and Corporationrationrate Secretary, 2015 to present Executive Vice President, General Counsel. since 2015.
Age | 57 |
Tenure | 9 years |
Phone | 212-546-4000 |
Web | http://www.bms.com |
Similar Executives
Showing other executives | EXECUTIVE Age | ||
Nobuaki Tanaka | Astellas Pharma | N/A | |
Victoria Whyte | GlaxoSmithKline PLC ADR | N/A | |
Yasuhiro Kanzaki | Astellas Pharma | N/A | |
Thomas Elsner | Bayer Aktiengesellschaft | 59 | |
F Hoffmann | Roche Holding AG | N/A | |
Sef Kurstjens | Astellas Pharma | N/A | |
Katzumi Ozawa | Astellas Pharma | N/A | |
John Reed | Roche Holding AG | 59 | |
Gottlieb Keller | Roche Holding Ltd | 64 | |
Erwin Vanhaecke | Novartis AG ADR | N/A | |
Aharon Gal | Novartis AG ADR | N/A | |
Shiro Yamamoto | Astellas Pharma | N/A | |
Norbert Bischofberger | Bayer Aktiengesellschaft | 62 | |
Michael Koenig | Bayer Aktiengesellschaft | 50 | |
Yukio Matsui | Astellas Pharma | N/A | |
Andrin Oswald | Novartis AG | 41 | |
Michele Galen | Novartis AG ADR | N/A | |
Klaus Moosmayer | Novartis AG | 55 | |
Clemens Boersig | Bayer Aktiengesellschaft | 68 | |
Bertrand Bodson | Novartis AG | 43 | |
Satoru Kimura | Daiichi Sankyo | N/A |
Bristol Myers Squibb Leadership Team
Elected by the shareholders, the Bristol-Myers Squibb's board of directors comprises two types of representatives: Bristol-Myers Squibb inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bristol-Myers. The board's role is to monitor Bristol-Myers Squibb's management team and ensure that shareholders' interests are well served. Bristol-Myers Squibb's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bristol-Myers Squibb's outside directors are responsible for providing unbiased perspectives on the board's policies.
Ann Powell, Chief Human Resource Officer, Senior Vice President | ||
Togo West, Independent Director | ||
Karen Vousden, Director | ||
Adam Dubow, Senior Vice President Chief Compliance Officer and Ethics Officer | ||
Alan Lacy, Independent Director | ||
Robert Bertolini, Independent Director | ||
Jose Baselga, Independent Director | ||
Charles Bancroft, CFO, Executive Vice President | ||
Gerald Storch, Independent Director | ||
Louis Schmukler, President - Global Manufacturing and Supply | ||
Michael Grobstein, Independent Director | ||
Christopher Boerner, Executive Vice President and Chief Commercial Officer | ||
John Elicker, Senior Vice President - Public Affairs and Investor Relations | ||
Anne Nielsen, Senior Vice President Chief Compliance and Ethics Officer | ||
Karen Santiago, Senior Vice President Controller | ||
Giovanni Caforio, COO, Director | ||
Vicki Sato, Independent Director | ||
Emmanuel Blin, Senior Vice President Chief Strategy Officer | ||
Joseph Caldarella, Senior Vice President Corporate Controller | ||
Laurie Glimcher, Independent Director | ||
Murdo Gordon, Executive Vice President Chief Commercial Officer | ||
Lamberto Andreotti, CEO, Director | ||
Thomas Lynch, Independent Director | ||
Dinesh Paliwal, Independent Director | ||
Lewis Campbell, Independent Director | ||
Theodore Samuels, Independent Director | ||
Samuel Moed, Senior Vice President - Strategic Planning and Analysis | ||
Matthew Emmens, Independent Director | ||
Ann Judge, Senior Vice President - Global Human Resources | ||
Sandra Leung, General Counsel, Corporate Secretary | ||
Paul Autenried, Senior Vice President - Enterprise Services, CIO | ||
Francis Cuss, Executive Vice President Chief Scientific Officer | ||
Paul Biondi, Senior Vice President Head - Business Development | ||
Peter Arduini, Independent Director |
Bristol-Myers Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Bristol-Myers Squibb a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Revenue | 46.38 B | |||
EBITDA | 20.1 B | |||
Net Income | 7.01 B | |||
Cash And Equivalents | 6.07 B | |||
Cash Per Share | 3.72 X | |||
Total Debt | 39.6 B | |||
Debt To Equity | 59.40 % | |||
Current Ratio | 1.40 X | |||
Book Value Per Share | 7.55 X | |||
Cash Flow From Operations | 16.21 B |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Other Consideration for investing in Bristol-Myers Pink Sheet
If you are still planning to invest in Bristol Myers Squibb check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bristol-Myers Squibb's history and understand the potential risks before investing.
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Stocks Directory Find actively traded stocks across global markets | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance |